Literature DB >> 29935939

Modulation of acute effects of delta-9-tetrahydrocannabinol on psychotomimetic effects, cognition and brain function by previous cannabis exposure.

Marco Colizzi1, Philip McGuire1, Vincent Giampietro2, Steve Williams2, Mick Brammer2, Sagnik Bhattacharyya3.   

Abstract

Cannabis use has been associated with psychosis and cognitive dysfunction. Some evidence suggests that the acute behavioral and neurocognitive effects of the main active ingredient in cannabis, (-)-trans-Δ9-tetrahydrocannabinol (∆9-THC), might be modulated by previous cannabis exposure. However, this has not been investigated either using a control group of non-users, or following abstinence in modest cannabis users, who represent the majority of recreational users. Twenty-four healthy men participated in a double-blind, randomized, placebo-controlled, repeated-measures, within-subject, ∆9-THC challenge study. Compared to non-users (N=12; <5 lifetime cannabis joints smoked), abstinent modest cannabis users (N=12; 24.5±9 lifetime cannabis joints smoked) showed worse performance and stronger right hemispheric activation during cognitive processing, independent of the acute challenge (all P≤0.047). Acute ∆9-THC administration produced transient anxiety and psychotomimetic symptoms (all P≤0.02), the latter being greater in non-users compared to users (P=0.040). Non-users under placebo (control group) activated specific brain areas to perform the tasks, while deactivating others. An opposite pattern was found under acute (∆9-THC challenge in non-users) as well as residual (cannabis users under placebo) effect of ∆9-THC. Under ∆9-THC, cannabis users showed brain activity patterns intermediate between those in non-users under placebo (control group), and non-users under ∆9-THC (acute effect) and cannabis users under placebo (residual effect). In non-users, the more severe the ∆9-THC-induced psychotomimetic symptoms and cognitive impairments, the more pronounced was the neurophysiological alteration (all P≤0.036). Previous modest cannabis use blunts the acute behavioral and neurophysiological effects of ∆9-THC, which are more marked in people who have never used cannabis.
Copyright © 2018 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Cannabis use; Cognitive functioning; Delta-9-tetrahydrocannabinol; Functional Magnetic Resonance Imaging; Psychosis; Tolerance

Mesh:

Substances:

Year:  2018        PMID: 29935939     DOI: 10.1016/j.euroneuro.2018.04.003

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  10 in total

Review 1.  The why behind the high: determinants of neurocognition during acute cannabis exposure.

Authors:  Johannes G Ramaekers; Natasha L Mason; Lilian Kloft; Eef L Theunissen
Journal:  Nat Rev Neurosci       Date:  2021-05-27       Impact factor: 34.870

2.  Effects of cannabidiol in cannabis flower: Implications for harm reduction.

Authors:  Laurel P Gibson; Hollis C Karoly; Jarrod M Ellingson; Jost Klawitter; Cristina Sempio; Julia E Squeri; Angela D Bryan; L Cinnamon Bidwell; Kent E Hutchison
Journal:  Addict Biol       Date:  2021-08-31       Impact factor: 4.093

Review 3.  The Autism-Psychosis Continuum Conundrum: Exploring the Role of the Endocannabinoid System.

Authors:  Marco Colizzi; Riccardo Bortoletto; Rosalia Costa; Sagnik Bhattacharyya; Matteo Balestrieri
Journal:  Int J Environ Res Public Health       Date:  2022-05-05       Impact factor: 4.614

4.  Descriptive Psychopathology of the Acute Effects of Intravenous Delta-9-Tetrahydrocannabinol Administration in Humans.

Authors:  Marco Colizzi; Nathalie Weltens; Philip McGuire; Lukas Van Oudenhove; Sagnik Bhattacharyya
Journal:  Brain Sci       Date:  2019-04-25

Review 5.  Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition.

Authors:  Marco Colizzi; Mirella Ruggeri; Sagnik Bhattacharyya
Journal:  Front Psychol       Date:  2020-05-14

Review 6.  A systematic review of neuroimaging and acute cannabis exposure in age-of-risk for psychosis.

Authors:  Lani Cupo; Eric Plitman; Elisa Guma; M Mallar Chakravarty
Journal:  Transl Psychiatry       Date:  2021-04-13       Impact factor: 6.222

7.  Higher Risk, Higher Reward? Self-Reported Effects of Real-World Cannabis Use in Parkinson's Disease.

Authors:  Samantha K Holden; Christopher H Domen; Stefan Sillau; Ying Liu; Maureen A Leehey
Journal:  Mov Disord Clin Pract       Date:  2022-01-28

8.  Cannabis Use in Autism: Reasons for Concern about Risk for Psychosis.

Authors:  Riccardo Bortoletto; Marco Colizzi
Journal:  Healthcare (Basel)       Date:  2022-08-16

Review 9.  Cannabis and Cognitive Functioning: From Acute to Residual Effects, From Randomized Controlled Trials to Prospective Designs.

Authors:  Josiane Bourque; Stéphane Potvin
Journal:  Front Psychiatry       Date:  2021-06-10       Impact factor: 4.157

Review 10.  Is the Adolescent Brain at Greater Vulnerability to the Effects of Cannabis? A Narrative Review of the Evidence.

Authors:  Grace Blest-Hopley; Marco Colizzi; Vincent Giampietro; Sagnik Bhattacharyya
Journal:  Front Psychiatry       Date:  2020-08-26       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.